Drug Discovery World
AUGUST 30, 2024
Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector. MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you elaborate on the status and the aims of your therapeutic pipeline?
Bio Pharma Dive
AUGUST 30, 2024
Detailed results from the Helios-B study support summary findings disclosed in June. But they may not make vutrisiran the standard of care as easily as Alnylam hopes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the CD44 Antigen pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Bio Pharma Dive
AUGUST 30, 2024
A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA approved a vaccine for mpox and a biotech planned layoffs.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the Aromatase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Fierce Pharma
AUGUST 30, 2024
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. | Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
AUGUST 30, 2024
As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus. | With the nod, Emergent's vaccine joins Bavarian Nordic's Jynneos as approved protection options to address the continued outbreak in Africa, which was recently deemed a public health emergency.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 85 drugs in development for Esophagitis by 74 companies/universities/institutes. The top development phase for Esophagitis is phase i, with 26 drugs in that stage.
pharmaphorum
AUGUST 30, 2024
Troubled UK biotech ReNeuron will cancel its AIM listing, saying it has been unable to raise the funds it needs to bring it out of administration
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 88 drugs in development for Esophageal Diseases by 77 companies/universities/institutes. The top development phase for Esophageal Diseases is phase i, with 28 drugs in that stage.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
AUGUST 30, 2024
Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 7 drugs in development for Peritoneal Tumor by seven companies/universities/institutes. The top development phase for Peritoneal Tumor is phase i, with three drugs in that stage.
Fierce Pharma
AUGUST 30, 2024
Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer for now in its home country. | Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer in its home country for now thanks to doubts around patients’ overall survival.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 28 drugs in development for Bacillary Dysentery (Shigellosis) by 20 companies/universities/institutes. The top development phase for Bacillary Dysentery (Shigellosis) is preclinical, with 16 drugs in that stage.
Drug Discovery World
AUGUST 30, 2024
News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for obesity, and a muscarinic M4 selective agonist for schizophrenia.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 6 drugs in development for Hepatobiliary System Tumor by six companies/universities/institutes. The top development phase for Hepatobiliary System Tumor is phase ii, with four drugs in that stage.
Fierce Pharma
AUGUST 30, 2024
Alnylam is circling the bases after walloping—in the words of chief medical officer Pushkal Garg M.D.—a “grand slam” with data that position its RNA silencer Amvuttra (vutrisiran) to potentially be | At the European Society of Cardiology conference in London, Alnylam presented positive data from the phase 3 HELIOS-B trial which assessed RNA silencer Amvuttra (vutrisiran) as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 13 drugs in development for Bronchiolitis by 13 companies/universities/institutes. The top development phase for Bronchiolitis is phase iii, with five drugs in that stage.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Discovery World
AUGUST 30, 2024
Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’ cancers.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 131 drugs in development for Respiratory Distress Syndrome by 119 companies/universities/institutes. The top development phase for Respiratory Distress Syndrome is preclinical, with 72 drugs in that stage.
pharmaphorum
AUGUST 30, 2024
BioMarin wields axe again, slashing 225 positions from its global workforce as it continues a major restructuring drive
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 8 drugs in development for Hepatitis E by eight companies/universities/institutes. The top development phase for Hepatitis E is preclinical, with two drugs in that stage.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Cloudbyz
AUGUST 30, 2024
In the rapidly evolving landscape of clinical research, data has become one of the most valuable assets. Clinical Trial Management Systems (CTMS) play a pivotal role in managing this data, encompassing everything from patient information and trial protocols to sensitive medical records and regulatory documents. Given the critical nature of this data, ensuring its security and compliance with regulatory standards is paramount.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 128 drugs in development for Cystic Fibrosis by 101 companies/universities/institutes. The top development phase for Cystic Fibrosis is preclinical, with 54 drugs in that stage.
XTalks
AUGUST 30, 2024
The pharma and biotech sectors have been leaders of innovation and economic growth in 2024. As this industry navigates evolving healthcare demands, it demonstrates remarkable resilience. This trend aligns with the broader surge in biotech stocks , which have outperformed many other sectors this year, fueled by a series of high-impact drug approvals, mergers and a promising pipeline of next-generation therapies.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the Cholecystokinin Receptor Type A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
XTalks
AUGUST 30, 2024
In this episode, Ayesha spoke with Steffen-Sebastian Bolz, MD, PhD, a scientist, physician and entrepreneur. He is a Co-Founder of Aphaia Pharma AG and Founder and Chief Scientific and Medical Officer at Qanatpharma AG. Dr. Bolz holds a full professorship at the University of Toronto, is a Principal Investigator at the Ted Rogers Centre for Heart Research and Director of the Toronto Centre for Microvascular Medicine.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the Procollagen Proline Dioxygenase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Cloudbyz
AUGUST 30, 2024
Let’s be real for a second—clinical research systems aren’t exactly everyone’s favorite topic but if you’re in the trenches of clinical research, you know they can make or break your day. So, let’s cut through the noise and talk about what’s really going on with these systems, why they’re driving everyone up the wall. It’s 2024—Almost 2025 soon—and We’re Still Struggling with things like: Reporting: Why Is It Such a Hassle?
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the Catechol O Methyltransferase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
59 
Let's personalize your content